Oral Ialoral® Forte versus ultrasound-guided intra-articular cortisone infiltration: results of a retrospective single-center study
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Osteoarthritis (OA) is a common cause of pain and functional limitation. We compared the analgesic and functional outcomes of Ialoral® Forte, a nutraceutical formulation, with those of ultrasound-guided intra-articular triamcinolone in patients with hip or knee OA and baseline Numeric Rating Scale (NRS) ≤5. This retrospective single-center study included 60 patients (NRS≤5, Kellgren-Lawrence grade I-II) treated between June 2022 and January 2023. Group A received oral Ialoral® Forte (two tablets daily for 40 days); group B underwent two ultrasound-guided intraarticular corticosteroid injections 20 days apart. Pain intensity (NRS) and joint function (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]) were evaluated at baseline and at 20, 40, 60, and 90 days. Both treatments significantly reduced pain and improved joint function over time. No statistically significant differences were observed between groups (p>0.05). Oral Ialoral® Forte achieved comparable analgesic and functional outcomes to intra-articular corticosteroids, without injection-related risks or contraindications. Oral Ialoral® Forte represents a safe, effective, and non-invasive alternative to intra-articular corticosteroid injections for the management of mild to moderate osteoarthritis, providing similar short-term pain relief and functional recovery with excellent tolerability.
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.